Compare BBN & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBN | NBTX |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 964.6M | 1.0B |
| IPO Year | 2010 | 2018 |
| Metric | BBN | NBTX |
|---|---|---|
| Price | $15.69 | $41.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | ★ 193.8K | 74.2K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 6.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.47 | $3.86 |
| 52 Week High | $17.45 | $57.14 |
| Indicator | BBN | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.64 | 49.82 |
| Support Level | $15.58 | $28.35 |
| Resistance Level | $16.71 | $41.89 |
| Average True Range (ATR) | 0.14 | 3.80 |
| MACD | -0.04 | -0.88 |
| Stochastic Oscillator | 31.05 | 33.03 |
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation. The Trust seeks to achieve its investment objectives by investing in a portfolio of taxable municipal securities, including Build America Bonds (BABs), issued by state and local governments to finance capital projects such as public schools, roads, transportation infrastructure, bridges, ports and public buildings.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.